STOCK TITAN

Halberd Corp - HALB STOCK NEWS

Welcome to our dedicated news page for Halberd (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Halberd's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Halberd's position in the market.

Rhea-AI Summary
Halberd 's LDN+ Drug Enters Safety Trial Protocol for Military Active Duty and Veterans under CRADA Contract, Signaling Promising Developments in Addressing Mental Health Issues
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Halberd Corporation's Traumatic Brain Injury (TBI) nasal spray testing protocols were approved by the Institutional Animal Care and Use Committee at Mississippi State University. The company plans to launch an advanced program after the successful Phase #1 pilot test program. The CEO expressed optimism about the results and secured non-dilutive funding for future expenditures. Halberd also executed a revenue sharing agreement with Athena for further technology development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Summary
Halberd Corporation's executives discuss the partnership with Athena GTX and its potential impact on advancing breakthrough technologies towards government contracts. The interview on 'The Street Reports' sheds light on the optimistic outlook for 2024. For more information, visit the Halberd Corporation website or listen to the podcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
partnership
Rhea-AI Summary
Halberd Corporation (HALB) made significant advances in technology development and business goals in 2023, achieving successful eradication of antibiotic-resistant bacteria and fungi, as well as significant progress in developing a nasal spray to counteract Traumatic Brain Injury (TBI). The company also secured non-dilutive funding and joint ventures for continued R&D, clinical trials, and FDA certification of its products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
none
-
Rhea-AI Summary
Halberd Corporation (HALB) announces revenue-sharing agreement with Athena GTX, Inc. for medical care solutions tailored for first responders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
-
Rhea-AI Summary
Halberd Corporation (HALB) formalizes revenue-sharing agreement with Athena GTX, Inc. specializing in medical care solutions for first responders. Athena has a successful history of securing government contracts, with 60% of its income historically coming from innovative research and development funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
none
Rhea-AI Summary
Halberd Corporation (HALB) and CrodenHealth.com of Canada have agreed to produce, market, sell, and distribute Halberd's patented low dose naltrexone combo products worldwide. The agreement also gives CrodenHealth.com the right of first refusal regarding similar rights to future products in Halberd's development pipeline. This partnership brings together the vast pharmaceutical sales and marketing expertise of CrodenHealth with Halberd Corporation's unique groundbreaking intellectual property and first-to-market products, ensuring a profitable positive impact on patient outcomes. The collaboration aims to create new and profitable revenue streams, marking the beginning of a long fruitful win-win relationship between the two entities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.29%
Tags
none
-
Rhea-AI Summary
Halberd Corporation (HALB) Extends Research Collaboration with Mississippi State University (MSU) for TBI Nasal Spray Project
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
partnership
-
Rhea-AI Summary
Halberd Corporation provides updates on important projects in recent interview
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
none
Rhea-AI Summary
Halberd Corporation's nasal spray testing results show promising reductions in biomarkers associated with Traumatic Brain Injury (TBI). Neuron Specific Enolase (NSE) reduced by 25% and Glial Fibrillary Acid Protein (GFAP) reduced by 52.3%. The results indicate potential breakthrough in TBI treatment. The company aims to perfect the formulation and looks forward to feedback from the Department of Defense.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
Halberd Corp

OTC:HALB

HALB Rankings

HALB Stock Data

1.82M
Data Processing, Hosting, and Related Services
Information
Link
US
Southfield